Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Bicycle TherapeuticsBCYC | Open-market sale | 04/02–04/06 | 04/06 | 2,404 sh2 trades | $4.94avg. | $11,877.14 | −1.5% | |
CEO | Bicycle TherapeuticsBCYC | Open-market sale | 04/02–04/06 | 04/06 | 7,683 sh2 trades | $4.94avg. | $37,963.77 | −1.2% |
Bicycle TherapeuticsBCYC | Open-market sale | 04/02–04/06 | 04/06 | 901 sh2 trades | $4.93avg. | $4,438.19 | −1.4% | |
Bicycle TherapeuticsBCYC | Open-market sale | 04/02–04/06 | 04/06 | 1,772 sh2 trades | $4.93avg. | $8,735.66 | −1.8% | |
Bicycle TherapeuticsBCYC | Open-market sale10b5-1 plan | 04/02–04/06 | 04/06 | 1,408 sh3 trades | $4.94avg. | $6,961.75 | −1.5% | |
Bicycle TherapeuticsBCYC | Open-market sale | 01/02–01/05 | 01/06 | 6,311 sh2 trades | $6.62avg. | $41,804.36 | −3.8% | |
CEO | Bicycle TherapeuticsBCYC | Open-market sale | 01/02–01/05 | 01/06 | 21,314 sh2 trades | $6.62avg. | $141,198.94 | −3.3% |
Bicycle TherapeuticsBCYC | Open-market sale | 01/02–01/05 | 01/06 | 6,660 sh2 trades | $6.63avg. | $44,126.56 | −4.6% | |
Bicycle TherapeuticsBCYC | Open-market sale10b5-1 plan | 01/02–01/05 | 01/06 | 7,623 sh3 trades | $6.62avg. | $50,488.52 | −8.0% | |
Bicycle TherapeuticsBCYC | Open-market sale | 01/02–01/05 | 01/06 | 2,432 sh2 trades | $6.64avg. | $16,147.35 | −3.5% | |
Bicycle TherapeuticsBCYC | Open-market sale | 01/02–01/05 | 01/06 | 5,194 sh2 trades | $6.64avg. | $34,490.75 | −5.0% | |
Bicycle TherapeuticsBCYC | Open-market sale | 25/10/02–25/10/03 | 25/10/06 | 1,802 sh2 trades | $8.41avg. | $15,146.58 | −1.5% | |
CEO | Bicycle TherapeuticsBCYC | Open-market sale | 25/10/02–25/10/03 | 25/10/06 | 5,494 sh2 trades | $8.41avg. | $46,181.91 | −1.1% |
Bicycle TherapeuticsBCYC | Open-market sale | 25/10/02–25/10/03 | 25/10/06 | 2,125 sh2 trades | $8.40avg. | $17,859.78 | −2.2% | |
Bicycle TherapeuticsBCYC | Open-market sale | 25/10/02–25/10/03 | 25/10/06 | 324 sh2 trades | $8.40avg. | $2,722.63 | −1.0% | |
Bicycle TherapeuticsBCYC | Open-market sale | 25/10/02–25/10/03 | 25/10/06 | 723 sh2 trades | $8.40avg. | $6,075.7 | −1.3% | |
Bicycle TherapeuticsBCYC | Open-market sale10b5-1 plan | 25/10/02 | 25/10/06 | 482 sh2 trades | $8.52avg. | $4,104.45 | −1.1% | |
Robert Charles SwantonDirector | Bicycle TherapeuticsBCYC | Open-market sale10b5-1 plan | 25/10/02 | 25/10/06 | 102 sh | $8.55 | $872.1 | −0.7% |
Bicycle TherapeuticsBCYC | Open-market sale | 25/07/02–25/07/03 | 25/07/07 | 1,791 sh2 trades | $7.28avg. | $13,036.29 | −1.5% | |
CEO | Bicycle TherapeuticsBCYC | Open-market sale | 25/07/02–25/07/03 | 25/07/07 | 5,461 sh2 trades | $7.29avg. | $39,836.04 | −1.1% |
